Small-Cap Investor Forum

[MissionIR]

Aldeyra Therapeutics (ALDX) Develops “Traps” to Capture Disease-Causing Toxins

Aldeyra Therapeutics is a biotechnology company developing a novel drug platform of drug candidates designed to trap free aldehydes, which are naturally occurring chemical species considered to be inflammatory-inducing, toxic links to many diseases, including autoimmune, inflammatory, and neurological diseases.

Aldeyra has developed a suite of “traps” designed to capture and eliminate free aldehydes, which ideally would allow for the treatment and prevention of disease, as well as slowed progression of chronic disease. In animal testing, the company’s lead compound, NS2, was generally safe and well-tolerated topically and systemically. In a phase 1evaluation trial in human subjects, NS2 was safe and well-tolerated when administered as an eye drop.

In 2014, the company plans to initiate the following studies for NS2: phase II trials in discoid lupus, acute anterior uveitis, and ocular rosacea; a phase III trial in the rare Sjogren-Larsson syndrome; and a phase I study to test the safety of an oral formulation of the candidate. For rare diseases, Aldeyra intends to pursue orphan drug designation of its platform from the United States Food and Drug Administration (FDA).

To raise capital to fund its clinical trials and to develop additional aldehyde traps for the treatment of other diseases, Aldeyra today made its market debut on the Nasdaq exchange with a $31.3 million initial public offering (IPO) of 2.2 million shares priced at $10-$11 a piece.

“We believe there is significant unmet medical need for the therapies we intend to develop. We are not aware of any therapy that has been approved by the United States Food and Drug Administration, or the FDA, for SLS or ocular rosacea with meibomian gland dysfunction. … We believe that NS2 has the potential to be the first in class of aldehyde traps for the diseases described above and potentially for inflammatory and other diseases generally. None of our products have been approved for sale in the United States or elsewhere,” the company stated, as reported by Nasdaq.com.

For more information visit http://www.aldeyra.com